BI/Lilly's Jardiance Crowned As Heart Failure Game Changer After EMPEROR-Preserved
'Unequivocal Benefit' Unveiled At ESC
The full dataset from the closely-watched study demonstrated that Jardiance showed a 21% reduction in the risk of cardiovascular death or hospitalization for HFpEF compared with placebo, a significantly greater benefit than seen with the only approved drug for the indication, Novartis's Entresto.
